Long-chain polyunsaturated fatty acids: Selected mechanisms of action on bone

NIH. Osteoporosis prevention D, and therapy. NIH Consensus Statement, vol. 17, March 27–29, 2000. p. 1–36. Watkins, 2000, Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats, J Nutr, 130, 2274, 10.1093/jn/130.9.2274 Kettler, 2001, Can manipulation of the ratios of essential fatty acids slow the rapid rate of postmenopausal bone loss?, Altern Med Rev, 6, 61 Albertazzi, 2002, Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention, Maturitas, 42, 13, 10.1016/S0378-5122(02)00022-1 Borland, 1931, Effects of a fat-free diet on the structure of the kidney in rats, Arch Pathol, 11, 687 Marum, 1946, Roentgenograohic observations in age atrophy and osteoporosis of the spine, Radiology, 46, 220, 10.1148/46.3.220 Stepankova, 1996, Essential fatty acid deficiency and bone fragility in rats, Folia Biol, 42, 257 Kruger, 1997, Calcium metabolism, osteoporosis and essential fatty acids: a review, Prog Lipid Res, 36, 131, 10.1016/S0163-7827(97)00007-6 Kokkinos, 1993, Dietary lipids, prostaglandin E2 levels, and tooth movement in alveolar bone of rats, Calcif Tiss Int, 53, 333, 10.1007/BF01351839 Weiss, 2005, Ratio of n-6 to n-3 fatty acids and bone mineral density in older adults: the Rancho Bernardo study, Am J Clin Nutr, 81, 934, 10.1093/ajcn/81.4.934 Salari, 2008, A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis, Med Sci Monit, 14, RA37 Moyad, 2005, An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part I, Urol Oncol, 23, 28, 10.1016/j.urolonc.2005.01.016 Atkinson, 1997, Incorporation of long-chain n-3 fatty acids in tissues and enhanced bone marrow cellularity with docosahexaenoic acid feeding in post-weanling Fischer 344 rats, Lipids, 32, 293, 10.1007/s11745-997-0036-x Simopolous, 2006, Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases, Biomed Pharmacother, 60, 502, 10.1016/j.biopha.2006.07.080 Calder, 2006, n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases, Am J Clin Nutr, 83, 1505S, 10.1093/ajcn/83.6.1505S Burdge, 2006, Dietary α-linolenic acid and health-related outcomes: a metabolic perspective, Nutr Res Rev, 19, 26, 10.1079/NRR2005113 Burdge, 2006, Metabolism of α-linolenic acid in humans, Prostaglandin Leukot Essent Fatty Acid, 75, 161, 10.1016/j.plefa.2006.05.013 Serhan, 2005, Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes and neuroprotectins, Curr Opin Clin Nutr Metab Care, 8, 115, 10.1097/00075197-200503000-00003 Serhan, 2002, Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammatory signals, J Exp Med, 196, 1025, 10.1084/jem.20020760 Kuhn, 2006, Inflammation and immune regulation by 12/15-lipoxygenases, Prog Lipid Res, 45, 334, 10.1016/j.plipres.2006.02.003 Shen, 1998, Thromboxanes: synthase and receptors, J Biomed Sci, 5, 153, 10.1007/BF02253465 Davies, 2004, Cyclo-oxugenase-3: axiom, dogma, anomaly, enigma or splice error? Not as easy as 1, 2, 3, J Pharm Sci, 7, 217 Watkins, 2001, Bioactive fatty acids: role in bone biology and bone cell function, Prog Lipid Res, 40, 125, 10.1016/S0163-7827(00)00016-3 Sun, 2003, Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice, J Bone Miner Res, 18, 1206, 10.1359/jbmr.2003.18.7.1206 Poulsen, 2008, Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega 3 intake, Am J Hematol, 83, 437, 10.1002/ajh.21170 Coetzee, 2007, Effects of arachidonic acid, docosahexaenoic acid and prostaglandin E2 on cell proliferation and morphology of MG-63 and MC3T3-E1 osteoblast-like cells, Prostaglandin Leukot Essent Fatty Acid, 76, 35, 10.1016/j.plefa.2006.10.001 Kruger, 2005, Is docosahexaenoic acid more effective than eicosapentaenoic acid for increasing calcium bioavailability, Prostaglandin Leukot Essent Fatty Acid, 73, 327, 10.1016/j.plefa.2005.08.001 Watkins, 2001, Omega-3 polyunsaturated fatty acids and skeletal health, Exp Biol Med, 226, 485, 10.1177/153537020122600601 Li, 1999, Dietary conjugated linoleic acids alter serum IGF-I and IGF binding protein concentrations and reduce bone formation in rats fed (n-6) or (n-3) fatty acids, J Bone Miner Res, 14, 1153, 10.1359/jbmr.1999.14.7.1153 Lau, 2009, Femur EPA and DHA are correlated with femur biomechanical strength in young fat-1 mice, J Nutr Biochem, 20, 453, 10.1016/j.jnutbio.2008.05.004 Baird, 2008, Varying ratios of omega 6:omega 3 fatty acids on the pre- and postmortem mineral density, bone ash and bone breaking strength of laying chickens, Poult Sci, 87, 323, 10.3382/ps.2007-00186 Watkins, 2003, Modulatory effect of omega 3 polyunsaturated fatty acids on osteoblast function and bone metabolism, Prostaglandin Leukot Essent Fatty Acid, 68, 387, 10.1016/S0952-3278(03)00063-2 Fernandes, 2008, Effects of n-3 fatty acids on autoimmunity and osteoporosis, Front Biosci, 13, 4015, 10.2741/2989 Heaney, 2005, Roles of vitamin D, n-3 polyunsaturated fatty acid, and soy isoflavones in bone health, J Am Diet Assoc, 1700, 10.1016/j.jada.2005.09.011 Das, 2000, Essential fatty acids and osteoporosis, Nutrition, 16, 386, 10.1016/S0899-9007(00)00262-8 Shen, 2006, Protective effect of dietary long-chain n-3 polyunsaturated fatty acids on bone loss in gonad-intact middle-aged male rats, Br J Nutr, 95, 462, 10.1079/BJN20051664 Hogstrom, 2007, n-3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 study, Am J Clin Nutr, 85, 803, 10.1093/ajcn/85.3.803 Kruger, 1998, Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis, Aging Clin Exp Res, 10, 385, 10.1007/BF03339885 Bassey, 2000, Lack of effects of supplementation with essential fatty acids one bone mineral density in health pre- and postmenopausal women: two randomised controlled trials of Efacal versus calcium alone, Br J Nutr, 83, 629, 10.1017/S0007114500000805 Griel, 2007, An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans, Nutr J, 6, 1, 10.1186/1475-2891-6-2 Trichopoulos, 1997, Energy intake and monounsaturated fat in relation to bone mineral density among women and men in Greece, Prev Med, 26, 395, 10.1006/pmed.1997.0160 MacDonald, 2004, Nutritional associations with bone loss during the menopausal transition: evidence of a beneficial effect of calcium, alcohol and fruit and vegetable nutrients and of a detrimental effect of fatty acids, Am J Clin Nutr, 79, 155, 10.1093/ajcn/79.1.155 Martinez-Ramirez, 2007, Dietary fat intake and the risk of osteoporotic fractures in the elderly, Eur J Clin Nutr, 61, 1114, 10.1038/sj.ejcn.1602624 Corwin, 2006, Dietary saturated fat intake is inversely associated with bone density in humans: analysis of NHANES III, J Nutr, 136, 159, 10.1093/jn/136.1.159 Collins, 1991, Effect of prostaglandins E1, E2, and F2a on osteoclast formation in mouse bone marrow cultures, J Bone Miner Res, 6, 157, 10.1002/jbmr.5650060209 Jee, 1997, The in vivo anabolic actions of prostaglandins in bone, Bone, 21, 297, 10.1016/S8756-3282(97)00147-6 McCarthy, 1991, Prostaglandin E2 stimulates insulin-like growth factor I synthesis in osteoblast-enriched cultures from fetal rat bone, Endocrinology, 128, 2895, 10.1210/endo-128-6-2895 Corwin, 2003, Effects of dietary fats on bone health in advanced age, Prostaglandin Leukot Essent Fatty Acid, 68, 379, 10.1016/S0952-3278(03)00062-0 Weiler, 2002, Dietary long-chain polyunsaturated fatty acids minimize dexamethasone-induced reductions in arachidonic acid status but not bone mineral content in piglets, Pediatr Res, 51, 282, 10.1203/00006450-200203000-00004 Raisz, 1989, Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture, Prostaglandins, 37, 615, 10.1016/0090-6980(89)90076-2 Laneuville, 1995, Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2, J Biol Chem, 270, 19330, 10.1074/jbc.270.33.19330 Cunnane, 2002, Nutrition and metabolism of lipids, 81 Barham, 2000, Addition of eicosapentaenoic acid to γ-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans, J Nutr, 130, 1925, 10.1093/jn/130.8.1925 Lucia, 2003, Dietary arachidonic acid suppresses bone turnover in contrast to low dosage exogenous prostaglandin E2 that elevates bone formation in the piglet, Prostaglandin Leukot Essent Fatty Acid, 68, 407, 10.1016/S0952-3278(03)00065-6 Weiler, 2000, Dietary supplementation of arachidonic acid is associated with higher whole body weight and bone mineral density in growing pigs, Pediatr Res, 47, 692, 10.1203/00006450-200005000-00022 Burke, 2002, The effect of prostaglandin E2 (PGE2) and long-chain polyunsaturated fatty acids (LC PUFA) on bone formation in piglets: a model for bone growth in nutritional investigation, Prostaglandin Leukot Essent Fatty Acid, 67, 229, 10.1054/plef.2002.0424 Weiler, 2002, Modulation of essential (n-6):(n-3) fatty acids ratio alters fatty acid status but not bone mass in piglets, J Nutr, 132, 2667, 10.1093/jn/132.9.2667 Watkins, 1996, Dietary (n-3) and (n-6) polyunsaturates and acetylsalicylic acid alter ex vivo PGE2 biosynthesis, tissue IGF-I levels, and bone morphometry in chicks, J Bone Miner Res, 11, 1321, 10.1002/jbmr.5650110917 Tian, 2008, Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats, Bone, 42, 914, 10.1016/j.bone.2007.12.228 Gao, 2009, Effects of prostaglandin E2 on bone in mice in vivo, Prostaglandin Other Lipid Mediat, 89, 20, 10.1016/j.prostaglandins.2009.03.003 Tsujisawa, 2005, SC-19220, antagonist of prostaglandin E2 receptor EP1, inhibits osteoclastogenesis by RANKL, J Bone Miner Res, 20, 15, 10.1359/jbmr.2005.20.1.15 Li, 2000, Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro, Endocrinology, 141, 2054, 10.1210/en.141.6.2054 Ono, 2005, Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor, J Bone Miner Res, 20, 23, 10.1359/jbmr.2005.20.1.23 Tsutsumi, 2009, PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysis, J Bone Miner Res, 24, 1753, 10.1359/jbmr.090412 Liu, 2006, Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system, Ann NY Acad Sci, 1068, 225, 10.1196/annals.1346.047 Kaneko, 2007, Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells, Prostaglandin Leukot Essent Fatty Acid, 77, 181, 10.1016/j.plefa.2007.09.002 Take, 2005, Prostaglandin E2 strongly inhibits human osteoclast formation, Endocrinology, 146, 5204, 10.1210/en.2005-0451 Minamizaki, 2009, EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures, Bone, 44, 1177, 10.1016/j.bone.2009.02.010 Weinreb, 2006, Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity, Prostaglandin Leukot Essent Fatty Acid, 75, 81, 10.1016/j.plefa.2006.06.004 Suda, 2004, Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lypopolysaccharide induced osteoclast formation, J Immunol, 172, 2504, 10.4049/jimmunol.172.4.2504 Ramirez-Yanez, 2006, Prostaglandin E2 enhances transforming growth factor-beta 1 and TGF-beta receptor synthesis: an in vivo and in vitro study, Prostaglandin Leukot Essent Fatty Acid, 74, 183, 10.1016/j.plefa.2006.01.003 Tang, 2009, TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation, Nat Med, 15, 757, 10.1038/nm.1979 Sankar, 1995, Expression of transforming growth factor type III receptor in vascular endothelial cells increases their responsiveness to transforming growth factor beta 2, J Biol Chem, 270, 13567, 10.1074/jbc.270.22.13567 McCarthy, 2007, Prostaglandin E2 increases transforming growth factor-β type ii receptor expression through CCAAT enhancer-binding protein δ in osteoblasts, Mol Endocrinol, 21, 2713, 10.1210/me.2007-0210 Watkins, 2000, Conjugated linoleic acid and bone biology, J Am Coll Nutr, 19, 478S, 10.1080/07315724.2000.10718951 Schmid, 1992, Prostaglandin E2 stimulates synthesis of insulin-like growth factor binding protein-3 in rat bone cells in vitro, J Bone Miner Res, 7, 1157, 10.1002/jbmr.5650071007 Delany, 1994, Cellular and clinical perspectives on skeletal insulin-like growth factor I, J Cell Biochem, 55, 328, 10.1002/jcb.240550309 Lieberman, 2002, The role of growth factors in the repair of bone. Biology and clinical applications, J Bone Joint Surg, 84A, 1032, 10.2106/00004623-200206000-00022 McCarthy, 1994, Complex pattern of insulin-like growth factor binding protein expression in primary rat osteoblast enriched cultures: regulation by prostaglandin E2, growth hormone, and the insulin-like growth factors, J Cell Physiol, 160, 163, 10.1002/jcp.1041600119 Wang, 2006, Role of IGF-1 signalling in regulating osteoclastogenesis, J Bone Miner Res, 21, 1350, 10.1359/jbmr.060610 DiBattista, 1996, Prostaglandin E2 up-regulates insulin-like growth factor binding protein-3 expression and synthesis in human articular chondrocytes by a c-AMP-independent pathway: role of calcium and protein kinase A and C, J Cell Biochem, 63, 320, 10.1002/(SICI)1097-4644(19961201)63:3<320::AID-JCB7>3.0.CO;2-Z Raisz, 1993, Bone cell biology: new approaches and unanswered questions, Bone Miner Res, 8, S457, 10.1002/jbmr.5650081306 Hakeda, 1993, J Bone Miner Res, 8, S237 Kim, 2000, Inhibition of Caco-2 cell proliferation by n-3 fatty acids: possible mediation by increased secretion of insulin-like growth factor binding protein-6, Nutr Res, 20, 1409, 10.1016/S0271-5317(00)80022-6 Bianco, 2001, Bone marrow stromal stem cells: nature, biology, and potential applications, Stem Cell, 19, 180, 10.1634/stemcells.19-3-180 Maeda, 2002, Sortilin is upregulated during osteoblastic differentiation of mesenchymal stem cells and promotes extracellular matrix mineralization, J Cell Physiol, 193, 73, 10.1002/jcp.10151 Ducy, 1997, Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation, Cell, 89, 747, 10.1016/S0092-8674(00)80257-3 Karsenty, 2001, Minireview: transcriptional control of osteoblast differentiation, Endocrinology, 142, 2731, 10.1210/en.142.7.2731 Takada, 2008, Molecular mechanism of switching adipocyte/osteoblast differentiation through regulation of PPAR-gamma function, Clin Calcium, 18, 656 LeBlanc, 2008, Effect of dietary supplementation with fish oil on in vivo production of inflammatory mediators in clinically normal dogs, Am J Vet Res, 69, 486, 10.2460/ajvr.69.4.486 Zhang, 2002, Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair, J Clin Invest, 109, 1405, 10.1172/JCI0215681 Arikawa, 2004, Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells, J Cell Physiol, 200, 400, 10.1002/jcp.20031 Skillington, 2002, Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes, J Cell Biol, 159, 135, 10.1083/jcb.200204060 Liu, 2005, The interferon-inducible p204 protein acts as a transcriptional coactivator of Cbfa1 and enhances osteoblast differentiation, J Biol Chem, 280, 2788, 10.1074/jbc.M412604200 Giaginis, 2007, Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism, Fundam Clin Pharmacol, 21, 231, 10.1111/j.1472-8206.2007.00486.x Holmen, 2005, Essential role of beta-catenin in postnatal bone acquisition, J Biol Chem, 280, 21162, 10.1074/jbc.M501900200 Boyce, 2008, Functions of RANKL/RANK/OPG in bone modeling and remodeling, Arch Biochem Biophys, 473, 139, 10.1016/j.abb.2008.03.018 Poulsen, 2008, Long chain polyunsaturated fatty acids alter membrane bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells, Prostaglandin Lipid Mediat, 85, 42048, 10.1016/j.prostaglandins.2007.10.004 Coetzee, 2007, Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E2 (PGE2) and parathyroid hormone on osteoprotegerin (OPG) and RANKL secretion by MC3T3-E1 osteoblast-like cells, J Nutr Biochem, 18, 54, 10.1016/j.jnutbio.2006.03.002 Bhattacharya, 2005, Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Faslpr mice by n-3 fatty acids, J Am Coll Nutr, 24, 200, 10.1080/07315724.2005.10719466 Rahman, 2008, Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells that eicosapentaenoic acid, J Cell Physiol, 214, 201, 10.1002/jcp.21188 Hasturk, 2006, RvE1 protects from local inflammation and osteoclst-mediated bone destruction in perionditis, FASEB, 20, 401, 10.1096/fj.05-4724fje Cornish, 2008, Modulation of osteoclastogenesis by fatty acids, Endocrinology, 149, 5688, 10.1210/en.2008-0111 Horowitz, 1993, Cytokines and estrogen in bone: anti-osteoporotic effects, Science, 260, 626, 10.1126/science.8480174 Caughey, 1996, The effect on human TNF alpha and IL-1 Beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil, Am J Clin Nutr, 63, 116, 10.1093/ajcn/63.1.116 Claassen, 1995, Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks, total urinary hydroxyproline, and bone calcium content, Bone, 16, 385S, 10.1016/S8756-3282(95)80481-1 Votta, 1994, Cytokine suppressive anti-inflammatory compounds inhibit bone resorption in vitro, Bone, 15, 533, 10.1016/8756-3282(94)90277-1 Priante, 2002, Fatty acids and cytokine mRNA expression in human osteoblastic cells: a specific effect of arachidonic acid, Clin Sci, 102, 403, 10.1042/CS20010213 Bordin, 2003, Arachidonic acid-induced IL-6 expression is mediated by PKC alpha activation in osteoblastic cells, Biochemistry, 42, 4485, 10.1021/bi026842n Skuladottir, 2007, The effects of omega 3 polyunsaturated fatty acids on TNF-alpha and IL-10 secretion by murine peritoneal cells in vitro, Lipids, 42, 699, 10.1007/s11745-007-3081-1 Bhattacharya, 2007, Effect of fish oil on bone density in ageing C57BL/6 female mice, J Nutr Biochem, 18, 372, 10.1016/j.jnutbio.2006.07.002 Cohen, 2005, Flaxseed oil and inflammation-associated bone abnormalities in interleukin-10 knockout mice, J Nutr Biochem, 16, 368, 10.1016/j.jnutbio.2005.01.008 Zeitlin, 2003, Effects of long-term administration of n-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice, J Cell Biochem, 90, 347, 10.1002/jcb.10620 Miggiano, 2005, Diet, nutrition and bone health, Clin Ther, 156, 47 Liu, 2005, Cross-talk between interleukin-6 and prostaglandin E2 signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system, Endocrinology, 146, 1991, 10.1210/en.2004-1167 Bragga, 2003, Differential effects of prostaglandin derived ω-6 and ω-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion, PNAS, 100, 1751, 10.1073/pnas.0334211100 Bannenberg, 2005, Molecular circuits of resolution: formation and actions of resolvins and protectins, J Immunol, 174, 4345, 10.4049/jimmunol.174.7.4345 Bannenberg, 2004, Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration, Br J Pharmacol, 143, 43, 10.1038/sj.bjp.0705912 Herrera, 2008, An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption, Br J Pharmacol, 155, 43, 10.1038/bjp.2008.367 Shen, 2008, Effect of long chain n-3 polyunsaturated fatty acids on inflammation mediators during osteoblastogenesis, J Med Food, 11, 105, 10.1089/jmf.2007.540 Priante, 2005, Specific effect of arachidonic acid on inducible nitric oxide synthase (iNOS) mRNA expression in human osteoblastic cells, Clin Sci, 109, 177, 10.1042/CS20040369 Fan, 2004, Nitric oxide regulates receptor activator of nuclear factor-kB ligand and osteoprotegerin expression in bone marrow stromal cells, Endocrinology, 145, 751, 10.1210/en.2003-0726 Das, 2002, Nitric oxide as the mediator of the antiosteoporotic actions of estrogen, statins, and essential fatty acids, Exp Biol Med, 227, 88, 10.1177/153537020222700202 Clarke, 2004, The multidimensional regulation of gene expression by fatty acids: polyunsaturated fatty acids as nutrient sensors, Curr Opin Lipidol, 15, 13, 10.1097/00041433-200402000-00004 Sampath, 2004, Polyunsaturated fatty acid regulation of gene expression, Nutr Rev, 62, 333, 10.1111/j.1753-4887.2004.tb00058.x Issemann, 1990, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature, 347, 645, 10.1038/347645a0 Desvergne, 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev, 20, 649, 10.1210/er.20.5.649 Juge-Aubry, 1997, DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: importance of the 5′-flanking region, J Biol Chem, 272, 25252, 10.1074/jbc.272.40.25252 Jurutka, 2007, Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutritional ligands, J Bone Miner Res, 22, V2, 10.1359/jbmr.07s216 Wan, 2007, PPAR-γ regulates osteoclastogenesis in mice, Nat Med, 13, 1496, 10.1038/nm1672 Ackert-Bicknell, 2008, PPARG by dietary fat interaction influences bone mass in mice and humans, J Bone Miner Res, 23, 1398, 10.1359/jbmr.080419 Lecka-Czernik, 2007, Activation of peroxisome proliferator-activated receptor-γ (PPARγ) by rosiglitazone suppresses components of the IGF regulatory system in vitro and in vivo, Endocrinology, 148, 903, 10.1210/en.2006-1121 Diascro, 1998, High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells, J Bone Miner Res, 13, 96, 10.1359/jbmr.1998.13.1.96 Nuttal, 1998, Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders, J Bone Miner Res, 13, 381, 10.1359/jbmr.1998.13.3.371 Lecka-Czernik, 1999, Inhibition of Osf/Cbfa 1 expression and terminal osteoblast differentiation bt PPARγ2, J Cell Biochem, 74, 357, 10.1002/(SICI)1097-4644(19990901)74:3<357::AID-JCB5>3.0.CO;2-7 Lin, 2007, PPARγ inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats, Bone, 41, 562, 10.1016/j.bone.2007.06.017 Jackson, 2000, Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts, FEBS Lett, 471, 119, 10.1016/S0014-5793(00)01372-7 Hasegawa, 2008, The PPARgamma-elective ligand BRL-49653 differentially regylates the fate choices of rat calvaria versus rat bone marrow stromal cell populations, BMC Dev Biol, 8, 71, 10.1186/1471-213X-8-71 Takada, 2008, A new PPAR-γ function in bone, IBMS BoneKEy, 5, 258, 10.1138/20080326 Lecka-Czernik, 2002, Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation, Endocrinology, 143, 2376, 10.1210/en.143.6.2376 Kliewer, 1997, Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ, Proc Natl Acad Sci USA, 94, 4318, 10.1073/pnas.94.9.4318 Berger, 2002, The mechanisms of action of PPARγ, Annu Rev Med, 53, 409, 10.1146/annurev.med.53.082901.104018 Still, 2008, The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo, Calcif Tiss Int, 83, 285, 10.1007/s00223-008-9175-9 Kersten, 2000, Role of PPARs in health and disease, Nature, 405, 421, 10.1038/35013000 Rosen, 2001, PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth, J Biol Chem, 276, 37731, 10.1074/jbc.R100034200 Maurin, 2005, Expression of PPARγ and β/δ in human primary osteoblastic cells: influence of polyunsaturated fatty acids, Calcif Tiss Int, 76, 385, 10.1007/s00223-004-0108-y Abedin, 2006, n-3 Fatty acids inhibit vascular calcification via the p38-mitogen-activated protein kinase and peroxisome proliferator-activated receptor-γ pathways, Circ Res, 98, 727, 10.1161/01.RES.0000216009.68958.e6 Fyffe, 2006, Recombinant human PPAR-β/δ ligand binding domain is locked in an activated conformation by endogenous fatty acids, J Mol Biol, 356, 1005, 10.1016/j.jmb.2005.12.047 Mehrabian, 2005, Integrating genotypic and expression data in a segregating mouse population to identify 5-lipoxygenase as a susceptibility gene for obesity and bone traits, Nat Genet, 37, 1224, 10.1038/ng1619 Syversen, 2009, Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone, BMC Endocr Disord, 9, 10, 10.1186/1472-6823-9-10 Shibata, 2000, Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats, Br J Pharmacol, 130, 495, 10.1038/sj.bjp.0703328 Poulsen, 2007, Long chain fatty acids and the regulation of bone metabolism, Exp Biol Med, 232, 1275, 10.3181/0704-MR-100